Non-alcoholic fatty liver disease historical perspective: Difference between revisions

Jump to navigation Jump to search
Line 3: Line 3:
'''Editor in Chief''': Elliot Tapper, M.D., Beth Israel Deaconess Medical Center, [[User:C Michael Gibson |C. Michael Gibson, M.S., M.D.]] [mailto:charlesmichaelgibson@gmail.com]
'''Editor in Chief''': Elliot Tapper, M.D., Beth Israel Deaconess Medical Center, [[User:C Michael Gibson |C. Michael Gibson, M.S., M.D.]] [mailto:charlesmichaelgibson@gmail.com]
==Overview==
==Overview==
NAFLD/NASH was first described in a 1980 series of [[obese]], non-alcoholic patients of the [[Mayo Clinic]].<ref>Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434-438. PMID 7382552.</ref> Since that seminal description, our understanding of [[NAFLD]] has progressed minimally. <ref>Day, CP. Non-alcoholic steatohepatitis (NASH): where are we now and where are we going? Gut. 2002 May; 50(5): 585–588.</ref> The disease is most closely associated with the increasing [[obesity]], [[insulin resistance]], [[type two diabetes mellitus]] and [[hyperlipidemia]] [[endemic]] to the developed world. Roughly half of all patients with [[NAFLD]], however, do not meet criteria for [[metabolic syndrome]]. <ref>Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006;43:S99–S112.</ref>
NAFLD/NASH was first described in a 1980 series of [[obese]], non-alcoholic patients of the [[Mayo Clinic]].<ref>Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434-438. PMID 7382552.</ref> Since that seminal description, our understanding of [[NAFLD]] has progressed minimally. <ref>Day, CP. Non-alcoholic steatohepatitis (NASH): where are we now and where are we going? Gut. 2002 May; 50(5): 585–588.</ref>


==References==
==References==

Revision as of 17:37, 28 March 2013

Non-Alcoholic Fatty Liver Disease Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Non-Alcoholic Fatty Liver Disease from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case studies

Case #1

Non-alcoholic fatty liver disease historical perspective On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Non-alcoholic fatty liver disease historical perspective

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Non-alcoholic fatty liver disease historical perspective

CDC on Non-alcoholic fatty liver disease historical perspective

Non-alcoholic fatty liver disease historical perspective in the news

Blogs on Non-alcoholic fatty liver disease historical perspective

Directions to Hospitals Treating Non-alcoholic fatty liver disease

Risk calculators and risk factors for Non-alcoholic fatty liver disease historical perspective

Editor in Chief: Elliot Tapper, M.D., Beth Israel Deaconess Medical Center, C. Michael Gibson, M.S., M.D. [1]

Overview

NAFLD/NASH was first described in a 1980 series of obese, non-alcoholic patients of the Mayo Clinic.[1] Since that seminal description, our understanding of NAFLD has progressed minimally. [2]

References

  1. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434-438. PMID 7382552.
  2. Day, CP. Non-alcoholic steatohepatitis (NASH): where are we now and where are we going? Gut. 2002 May; 50(5): 585–588.

Template:WH Template:WS